Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
Date:6/30/2008

a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit http://www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
2. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
3. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
4. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
5. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
6. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
7. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
8. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
9. Nanotube forests grown on silicon chips for future computers, electronics
10. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
11. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), ... and Mr. David Pendarvis to its board of ... ,, Kenneth F. Buechler, Ph.D., was president, chief ... 1988 to 1994, Dr. Buechler was Biosite,s director ... was a senior research scientist for the diagnostics ...
(Date:12/16/2009)... the ultimate CHO cell culture supplement? InVitria has what scientists ... culture media supplement that improves the growth and productivity of ... performance, Zap-CHO is an animal free, well defined and consistent ... ... Collins, CO (PRWEB) December 16, 2009 -- Scientists working with ...
(Date:12/16/2009)... introduces HSP-A Soy Peptone. HSP A has been found to ... ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ... Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), ... improve growth rates and yields. HSP-A has been found to ...
(Date:12/15/2009)... -- Epeius Biotechnologies Corporation, an emerging leader in ... validation of the cutting-edge science behind its lead ... the world rediscovered the Cyclin G1 gene ... pathogenesis and disease progression, and thus a prime ... NIH National Cancer Institute investigating the role of ...
Breaking Biology Technology:Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
... of improving business processes with enterprise-centric Internet tools is hardly ... of adoption means that reluctant business leaders need an education ... hardly be attributed to a lack of information. Building on ... Web 2.0? " bloggers like Dion Hinchcliffe , ...
... growing belief that whenever a state company is acquired by ... the state's economy. But the recent acquisition of Madison's ... . has a real chance to benefit both parties and ... ,The win-win view not only was offered by executives in ...
... - Five University of Wisconsin-Madison faculty have ... the National Academies . , ,Election to the National ... , the National Academy of Engineering , the ... - is considered one of the highest honors accorded ...
Other Biology Technology:Businesses are slow to adopt Web 2.0 concepts 2Businesses are slow to adopt Web 2.0 concepts 3Businesses are slow to adopt Web 2.0 concepts 4Anatomy of a deal: CDW and Berbee 2Anatomy of a deal: CDW and Berbee 3Anatomy of a deal: CDW and Berbee 4
(Date:12/16/2009)... December 15, 2009 Signal Hill, CA Tom ... public and president of Bowman Global Change, has developed ... the fourth Intergovernmental Panel on Climate Change (IPCC) report ... to the authentic scientific information they need to make ... Bowman created the new format as a means to ...
(Date:12/16/2009)... NEW YORK, Dec. 1 iQor, a global ... in the 2009 InfoWorld 100 Awards Top ... system, TeQ21. This was the first submission for iQor. ... prestigious list of companies," said Vikas Kapoor, president and ... we do business, allowing us to work faster, smarter ...
(Date:12/16/2009)... Dec. 2 DigitalPersona, Inc., a ... today announced an agreement with IBM to ... biometric fingerprint technology on IBM SurePOS 500 ... allows point-of-sale applications to more easily and ... can be linked to the individuals who ...
Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Schwarzenegger Administration Sued for Allowing Health Insurance Companies to Deny Autism Care 50557 1Schwarzenegger Administration Sued for Allowing Health Insurance Companies to Deny Autism Care 50557 2Schwarzenegger Administration Sued for Allowing Health Insurance Companies to Deny Autism Care 50557 3Schwarzenegger Administration Sued for Allowing Health Insurance Companies to Deny Autism Care 50557 4Schwarzenegger Administration Sued for Allowing Health Insurance Companies to Deny Autism Care 50557 5Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 1Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 2Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 3Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 4Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 5Test Before Corneal Transplant May Improve Outcome 50548 1Test Before Corneal Transplant May Improve Outcome 50548 2
... developed the first small molecule that can reversibly activate ... the way for drugs that can treat low blood ... sodium channel (ENaC) controls sodium flow across many tissues ... is vital to maintaining proper salt balance and blood ...
... Lanka are three times more likely to suffer from ... ethnic Norwegians. This finding comes from the Norwegian Institute ... registered in the Medical Birth Registry of Norway over ... that 90 percent of pregnant women experience some degree ...
... Cancer Conference, jointly organized by the European Society for ... Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight ... development of lung cancer. , Experts agree that ... contributes to lung cancer development. But other factors can ...
Other Biology News:Extreme nausea and vomiting varies among pregnant women from different countries 2Viruses may play a role in lung cancer development 2